Mr. Doug Drysdale of Cybin reports

CYBIN TO ACQUIRE SMALL PHARMA INC.

Cybin Inc. and Small Pharma Inc. have entered into a definitive arrangement agreement pursuant to which Cybin will acquire all of Small Pharma's issued and outstanding securities in an all-share transaction pursuant to a plan of arrangement.

Under the terms of the transaction, Small Pharma shareholders will receive 0.2409 common shares in the capital of Cybin for each common share of Small Pharma held. The exchange ratio implies consideration of approximately 10 cents per Small Pharma share based on the closing price of the Cybin shares on the Cboe Canada exchange on Aug. 25, 2023, representing a 43.64-per-cent premium based on the 30-day volume-weighted average prices of the Cybin shares on the Cboe Canada exchange and the Small Pharma shares on the TSX Venture Exchange for the period ended on Aug. 25, 2023. As of the date of this press release, it is expected that existing Cybin shareholders and Small Pharma securityholders will own approximately 74.5 per cent and 25.5 per cent of Cybin, respectively.

The agreement has been unanimously approved by Small Pharma's board of directors on the unanimous recommendation of a special committee of its independent directors and Cybin's board of directors.

"This transaction creates a clear market leader in novel psychedelic therapeutics. The synergy of Cybin's and Small Pharma's development programs, intellectual property and robust datasets enhances our leadership and expertise in developing potentially best-in-class, optimized psychedelic therapeutics and positions the combined company to generate long-term value for all stakeholders. Our combined portfolios, having an increased number of potential value catalysts, also create added opportunities to support future funding activities with no added debt. We look forward to welcoming our Small Pharma colleagues into the Cybin team," said Doug Drysdale, chief executive officer of Cybin.

Small Pharma is a leader in the development of short-duration psychedelic therapies for mental health conditions, having raised a total of $63-million in capital since 2021 and demonstrating the first placebo-controlled efficacy results for N,N-dimethyltryptamine (DMT) in treating major depressive disorder (MDD). In the past years, Small Pharma has progressed two clinical-stage DMT-based programs and a pipeline of preclinical assets and developed a highly robust intellectual property (IP) portfolio to protect them.

With a common goal to create novel, optimized psychedelic-based therapeutics, the combination of Cybin and Small Pharma creates an international, clinical-stage leader with the potential to transform the treatment paradigm for mental health conditions. Cybin's and Small Pharma's combined DMT and deuterated DMT (dDMT) programs create the largest data set of systematic research on these short-duration psychedelic molecules. The companies' combined development portfolios are highly complementary and provide multiple opportunities to create operational and cost synergies.

The combined entity will hold the most impressive IP portfolio in the psychedelic drug development sector, with a combined 158 pending patent applications, including two allowed applications, and 28 granted patents protecting the combined companies' clinical and preclinical molecules. This extensive IP portfolio creates an unmatched opportunity for the combined company to develop next-generation novel compounds for a number of mental health disorders that may be amenable to treatment with psychedelic therapies.

George Tziras, chief executive officer of Small Pharma, said: "This marks the beginning of an exciting new chapter for Small Pharma. Since 2015, we have been committed to our mission of accelerating patient access to transformative mental health treatments, and I am incredibly proud of the progress we have made. Cybin shares both our vision and confidence in the potential of our programs. Cybin's senior listing on the NYSE American can also provide increased access to the broader and deeper capital markets of the United States. We look forward to combining the considerable strengths of our teams to create a category leader in novel psychedelic-based therapeutics and bring innovative mental health treatments to patients around the world."

Together, the combined operating teams of Cybin and Small Pharma create a sector-leading organization with deep expertise in DMT and deuterated psychedelic tryptamine-based therapeutics for mental health disorders. The integrated DMT data set from both companies represents an advanced and extensive DMT clinical program, including:

• Phase 2 safety and efficacy data for IV (intravenous) DMT in patients with MDD (SPL026);
• Extensive phase 1 data set for IV formulations of DMT and dDMT (CYB004e, CYB004, SPL026 and SPL028);
• Studies exploring more convenient and patient-friendly dosing methods (phase 1 intramuscular SPL026 and SPL028 and subcutaneous CYB004);
• Phase 1b safety and efficacy of SPL026 administered in conjunction with serotonin reuptake inhibitors (SSRIs) in patients with MDD, with data anticipated in late 2023; encouraging results could broaden access to DMT-based therapies by removing the requirement for patients to be withdrawn from existing SSRI medication.

Data readouts from both companies' phase 1 deuterated programs, CYB004 and SPL028, are anticipated by late 2023. This will enable a robust evaluation of formulations and administration routes and an informed, data-driven approach to launching a phase 2 efficacy study of dDMT in the United States early in 2024.

Cybin expects to report phase 2 safety and efficacy data from its CYB003 deuterated psilocybin analogue program in participants with MDD in late 2023. Plans are under way to scale the program for phase 3, including a partnership with a global clinical research organization, a streamlined EmbarkCT facilitator training program and preparations for good manufacturing practice (GMP) manufacturing of CYB003 capsules for pivotal clinical trial supplies. Cybin was recently granted a composition of matter patent covering a deuterated psilocybin analogue in its CYB003 program and anticipates the potential for receiving breakthrough therapy designation from the U.S. Food and Drug Administration (FDA), subject to FDA approval, as early as late 2023.

The combined company will be led by Cybin's chief executive officer, Mr. Drysdale, who brings over 30 years of experience in the health care sector. Small Pharma senior management and staff will be integrated with the existing Cybin team to create a highly experienced and skilled team that is well positioned to deliver on the development and clinical execution of the combined pipeline.

Additional transaction details

Pursuant to the transaction, Small Pharma shareholders will receive 0.2409 Cybin share for each Small Pharma share held. Holders of options to purchase Small Pharma shares that are in the money based on the volume-weighted average trading price of the Small Pharma shares on the TSX-V for the five trading days immediately preceding the effective time of the transaction will receive from Small Pharma a number of Small Pharma shares equal to the number of Small Pharma options held, multiplied by the amount by which the Small Pharma share value exceeds the exercise price of such Small Pharma options, divided by the Small Pharma share value. Such newly issued Small Pharma shares will be acquired by Cybin on the same terms as the other Small Pharma shares. Each Small Pharma option that is out of the money based on the Small Pharma share value will be deemed to be surrendered to Small Pharma for 0.1 cent and cancelled.

The transaction will be effected by way of a court-approved plan of arrangement under the Business Corporations Act (British Columbia), requiring the approval of at least 66-2/3rds per cent of the votes cast by the shareholders of Small Pharma voting in person, virtually or by proxy at an annual and special shareholder meeting to consider, in addition to certain annual business, the transaction. The issuance of Cybin shares pursuant to the transaction will also require approval by a simple majority of the votes cast by the shareholders of Cybin voting virtually or by proxy at an annual and special meeting of Cybin shareholders, in accordance with the policies of the Cboe Canada exchange. The shareholder meetings are expected to occur on or about Oct. 12, 2023.

In connection with the transaction, each of Small Pharma's directors and officers and Small Pharma's largest shareholder, who collectively beneficially hold or exercise control or direction over, directly or indirectly, an aggregate of approximately 28.8 per cent of the outstanding Small Pharma shares, have entered into voting and support agreements with Cybin, pursuant to which each of them has agreed, among other things, to support and vote their Small Pharma shares in favour of the transaction. In addition, each of Cybin's directors and officers and certain Cybin shareholders, who collectively hold or exercise control or direction over an aggregate of approximately 17 per cent of the outstanding Cybin shares, have entered into voting and support agreements with Small Pharma, pursuant to which each of them has agreed, among other things, to support and vote their Cybin shares in favour of the transaction.

In addition to shareholder approvals, the transaction is subject to approval by the Supreme Court of British Columbia, receipt of applicable stock exchange and regulatory approvals, including the approval of the TSX-V, and the satisfaction of certain other closing conditions customary in transactions of this nature. It is currently expected that the transaction will close in late October, 2023.

The agreement includes customary reciprocal non-solicitation covenants, subject in the case of fiduciary-out provisions that would permit Small Pharma to accept a superior proposal under certain circumstances, subject to a right-to-match period in favour of Cybin. The agreement also provides for reciprocal termination fees of $2-million payable to Cybin or Small Pharma if the transaction is terminated in certain specified circumstances, and, in certain other customary circumstances, expense reimbursement payable to Small Pharma of $400,000.

Upon completion of the transaction, the Cybin board will be increased by one director, and Mr. Tziras, the current chief executive officer of Small Pharma, will join the Cybin board.

Further information regarding the transaction will be included in the respective management information circulars of Cybin and Small Pharma, which will be mailed to shareholders in connection with their respective shareholder meetings. The agreement will be filed on the SEDAR+ profiles of Small Pharma and Cybin and with the U.S. Securities and Exchange Commission on EDGAR.

Boards of directors recommendations

The Small Pharma board has unanimously determined, after receiving the unanimous recommendation of the Small Pharma special committee, that the transaction is fair to the Small Pharma shareholders and in the best interests of Small Pharma and has unanimously recommended that Small Pharma shareholders vote in favour of the transaction. The Cybin board has unanimously determined that the transaction is in the best interests of Cybin and has unanimously recommended that Cybin shareholders vote in favour of the transaction.

The Small Pharma board has received the opinion of Jefferies International Ltd. to the effect that, as of Aug. 28, 2023, and based on and subject to the various assumptions made, procedures followed, matters considered and limitations and qualifications on the review undertaken set forth therein, the exchange ratio provided for pursuant to the agreement was fair, from a financial point of view, to the holders of Small Pharma shares (other than, as applicable, Cybin and its affiliates).

Upon completion of the transaction, it is expected that the Small Pharma shares will be delisted from the TSX-V and removed from the OTCQB market, and Small Pharma will cease to be a reporting issuer in each of the provinces and territories in Canada.

The combined company will remain headquartered in Toronto, with operations in Canada, the United States, the United Kingdom, the Netherlands and Ireland and will continue to trade on the NYSE American and the Cboe Canada exchange under the ticker CYBN.

Legal and financial advisers

Gowling WLG (Canada) LLP is acting as legal counsel to Cybin.

Aird & Berlis LLP is acting as legal counsel to Small Pharma and the Small Pharma special committee. Jefferies International is acting as exclusive financial adviser to Small Pharma.

Conference call and webcast details

Cybin and Small Pharma will host a conference call on Aug. 28, 2023, at 11:30 a.m. ET.

To join the conference call by telephone, please register on-line to receive the dial-in information.

To join the live audio webcast of the call, please register on-line.

The archived webcast will also be available on Cybin's investor relations website on the events and presentations page and on the investor page of Small Pharma's website under events and conferences.

About Cybin Inc.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.

Cybin's goal of revolutionizing mental health care is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. Cybin is currently developing CYB003, a proprietary deuterated psilocybin analogue for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder, and has a research pipeline of investigational psychedelic-based compounds.

Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland.

About Small Pharma Inc.

Small Pharma is a biotechnology company progressing a pipeline of short-duration psychedelic-assisted therapies for the treatment of mental health conditions. Small Pharma has a portfolio of clinical-stage DMT-based assets, SPL026 and SPL028. Small Pharma was granted an innovation passport designation for SPL026 from the United Kingdom Medicines and Healthcare products Regulatory Agency and has a pipeline of proprietary preclinical assets.

Small Pharma is focused on developing short-duration tryptamine-based therapeutics that are scalable, commercially differentiated and conveniently dosed, with the goal of addressing key unmet needs in the treatment of depression. Small Pharma's lead clinical-stage program, SPL026, a first-generation DMT molecule, has shown proof-of-concept for the potential treatment of MDD. In a phase 2a study, IV SPL026 demonstrated a rapid and durable antidepressant effect as well as a favourable safety and tolerability profile. Small Pharma is also advancing SPL028, a second-generation injectable deuterated DMT molecule, in a phase 1 trial.

We seek Safe Harbor.